Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 59.46M shares rose 1.6% year over year, in line with the +1.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.6% holds above the trailing-twelve-month pace of +1.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
59.46M+0.6% QoQ
Last fiscal yearDec 2025
58.93M+1.3% YoY
LTMMar 2026
59.11M+1.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.6%——
1 year+1.3%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
58.93M USD
Year-over-year change
+1.3%
4-year CAGR
+0.9%

Weighted Avg Shares (Diluted) vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 weighted avg shares (diluted) of 59.11M shares is the 4th highest of the 11 companies compared; the peer median is 48.76M shares.
  • Its year-over-year change of +1.3% is the 9th highest of 11, against a peer median of +6.4%.
  • Over three fiscal years its annual growth of +1.1% compares with a peer median of +15.3%.
VNDA Competitors Peer median
Weighted Avg Shares (Diluted) for VNDA and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.0%+15.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 202648.09M +39.5%+60.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +3.6%+9.8%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
SGMTSagimet Biosciences Inc.LTM Mar 202632.39M +0.9%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+0.4%
Peer median (excluding VNDA) 48.76M+6.4%+15.3%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue268.68M254.38M192.64M198.77M216.11M
Cost of Revenue25.63M24.28M14.8M11.31M13.04M
Gross Profit243.05M230.1M177.84M187.46M203.06M
Gross Margin90.5%90.5%92.3%94.3%94.0%
Research & Development75.36M85.77M76.82M74.43M109.27M
Selling, General & Admin124.05M136.49M112.88M146.41M237.95M
Operating Expenses200.89M223.77M191.8M228.12M354.23M
Depreciation & Amortization2.84M2.73M3.01M8.13M11.92M
EBITDA45.21M14.03M9.35M(14.79M)(126.73M)
EBITDA Margin16.8%5.5%4.9%-7.4%-58.6%
Operating Income42.17M6.33M(13.95M)(40.66M)(151.17M)
Operating Margin15.7%2.5%-7.2%-20.5%-70.0%
Interest Income199K0000
Interest Expense00000
Other Income / Expenses199K4.97M20.29M17.74M12.52M
Income Before Tax42.36M11.3M6.34M(22.92M)(138.65M)
Pre-Tax Margin15.8%4.4%3.3%-11.5%-64.2%
Income Tax Expense9.21M5.03M3.83M(4.02M)81.83M
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Net Margin12.3%2.5%1.3%-9.5%-102.0%
EPS (Basic)0.600.110.04(0.32)(3.74)
EPS (Diluted)0.580.110.04(0.32)(3.74)
Weighted Avg Shares55.55M56.46M57.38M58.15M58.93M
Weighted Avg Shares (Diluted)56.92M56.98M57.56M58.15M58.93M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.